I

    Immunovant Inc (IMVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $40.82
    -0.38 (-0.92%)

    Market Cap: $8.43B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(9/27)
    Avg Surprise
    -8.09%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.72
    Range$-0.76 - $-0.70
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.53+27.2%
    60d ago$-0.53+27.2%
    30d ago$-0.53+27.2%
    7d ago$-0.73-1.6%
    Current$-0.72
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.67
    Range$-0.77 - $-0.53
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.45+33.6%
    60d ago$-0.45+33.6%
    30d ago$-0.45+33.6%
    7d ago$-0.74-10.3%
    Current$-0.67
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.83---
    Dec 26EST
    		-$-0.67---
    Sep 26EST
    		-$-0.72---
    Jun 26
    Reported Aug 6
    		$-0.75$-0.66-13.64%Miss-5.6%
    Mar 26
    Reported May 20
    		$-0.67$-0.63-6.35%Miss-4.7%
    Dec 25
    Reported Feb 6
    		$-0.54$-0.69+21.74%Beat+28.9%
    Sep 25
    Reported Nov 10
    		$-0.65$-0.73+10.96%Beat+12.2%
    Jun 25
    Reported Aug 11
    		$-0.71$-0.67-5.97%Miss-18.3%
    Mar 25
    Reported May 29
    		$-0.64$-0.71+10.11%Beat-23.1%
    Dec 24
    Reported Feb 6
    		$-0.76$-0.75-1.33%Miss-111.1%
    Sep 24
    Reported Nov 6
    		$-0.74$-0.59-25.42%Miss-64.4%
    Jun 24
    Reported Aug 6
    		$-0.60$-0.52-15.38%Miss-5.3%
    Mar 24
    Reported May 29
    		$-0.52$-0.43-20.93%Miss-13.0%
    Dec 23
    Reported Feb 12
    		$-0.36$-0.42+14.29%Beat+26.5%
    Sep 23
    Reported Nov 9
    		$-0.45$-0.46+2.17%Beat-9.8%
    Jun 23
    Reported Aug 10
    		$-0.57$-0.44-29.55%Miss-62.9%
    Mar 23
    Reported May 22
    		$-0.46$-0.41-12.20%Miss-12.2%
    Dec 22
    Reported Feb 3
    		$-0.49$-0.37-32.43%Miss-36.1%
    Sep 22
    Reported Nov 4
    		$-0.41$-0.36-13.89%Miss-17.1%
    Jun 22
    Reported Aug 5
    		$-0.35$-0.40+12.50%Beat-12.9%
    Mar 22
    Reported Jun 8
    		$-0.41$-0.38-7.89%Miss-41.4%
    Dec 21
    Reported Feb 4
    		$-0.36$-0.31-16.13%Miss-12.5%
    Sep 21
    Reported Nov 5
    		$-0.35$-0.27-29.63%Miss-40.0%
    Jun 21
    Reported Aug 9
    		$-0.31$-0.31+0.00%Beat+18.4%
    Mar 21
    Reported Jun 1
    		$-0.29$-0.34+14.71%Beat+23.7%
    Dec 20
    Reported Feb 16
    		$-0.32$-0.25-28.00%Miss-14.3%
    Sep 20
    Reported Nov 12
    		$-0.25$-0.30+16.67%Beat+0.0%
    Jun 20
    Reported Aug 12
    		$-0.38$-0.33-15.15%Miss-3900.0%
    Mar 20
    Reported Jun 29
    		$-0.38$-0.28-35.71%Miss-
    Dec 19
    Reported Feb 14
    		$-0.28$-0.25-12.00%Miss-
    Sep 19
    Reported Nov 6
    		$-0.25$0.00N/AMiss-
    Jun 19
    Reported Aug 12
    		$0.01$0.00N/ABeat-
    Mar 19
    Reported Jun 12
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-15.64EV/EBITDA-14.12x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-80.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.27xQuick Ratio7.27x
    Trading Statistics
    Beta0.81Avg Volume1.14M
    52-Week High$45.4252-Week Low$14.58

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$43.45
    SMA 20$42.18
    SMA 50$40.33
    SMA 200$30.24
    EMA 10$42.60
    EMA 20$42.13
    EMA 50$39.77
    EMA 200$31.51

    MACD

    Line: 0.87Signal: 1.22Hist: -0.35

    ADX

    ADX: 20.1+DI: 22.3-DI: 30.3

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$45.33

    Bollinger Bands

    Upper Band$46.02
    Lower Band$38.34
    %B Position1821%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    45.6

    Momentum Oscillators

    Stoch %K42.0
    Stoch %D59.7
    Williams %R-83.6
    ROC (10d)-6.6%
    Momentum-2.89
    CCI (20d)-54.4
    MFI (14d)63.6

    Volatility Measures

    ATR (14d)$1.51(3.7%)
    StdDev (20d)1.92
    Hist Vol36.6%(Moderate)

    Volume Flow

    VWAP$40.67
    OBV38.7M
    AD Line38.5M
    CMF (20d)0.274

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio1.1x
    VWMA (20d)$42.19

    Pivot Points

    R3$44.98
    R2$44.18
    R1$42.69
    Pivot Point$41.89
    S1$40.40
    S2$39.60
    S3$38.11

    Advanced Oscillators

    TSI19.27
    Ultimate Osc46.1
    KST98.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.09M$0$0$0$0$160,000$0$0$0$1.50M$0$0
    Cost of RevenueN/AN/A$101,000$105,000$107,000$80,000$99,000$89,000$80,000$64,000$58,000$349,000
    Gross Profit$7.09MN/A$-101,000$-105,000$-107,000$80,000$-99,000$-89,000$-80,000$1.44M$-58,000$-349,000
    Operating Expenses$160.32M$159.55M$114.36M$131.76M$127.22M$113.83M$114.30M$115.74M$94.28M$80.88M$61.55M$61.80M
    R&D$142.63M$142.29M$98.92M$114.25M$101.20M$93.65M$94.52M$97.27M$75.47M$66.06M$48.34M$47.96M
    SG&A$17.69M$17.27M$15.44M$17.51M$26.02M$20.17M$19.78M$18.47M$18.81M$14.82M$13.21M$13.84M
    Operating Income$-153,228,000$-159,554,000$-114,362,000$-131,762,000$-127,224,000$-113,825,000$-114,302,000$-115,743,000$-94,281,000$-80,879,000$-61,553,000$-61,800,000
    Interest Income$7.09M$8.06M$5.33M$5.60M$6.34M$6.89M$4.59M$6.07M$7.18M$8.38M$8.93M$3.57M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-153,224,000$-150,700,000$-109,083,000$-125,908,000$-119,700,000$-105,866,000$-110,970,000$-109,041,000$-87,073,000$-75,087,000$-51,526,000$-58,208,000
    Income Tax Expense$0$-2,844,000$1.55M$594,000$913,000$583,000$152,000$78,000$77,000$232,000$-108,000$454,000
    Net Income$-153,224,000$-147,856,000$-110,635,000$-126,502,000$-120,613,000$-106,449,000$-111,122,000$-109,119,000$-87,150,000$-75,319,000$-51,418,000$-58,662,000
    EBITDA$-153,132,000$-150,604,000$-108,982,000$-125,803,000$-119,593,000$-105,757,000$-110,871,000$-108,952,000$-86,993,000$-75,023,000$-51,468,000$-58,152,000
    EBIT$-153,224,000$-150,700,000$-109,083,000$-125,908,000$-119,700,000$-105,866,000$-110,970,000$-109,041,000$-87,073,000$-75,087,000$-51,526,000$-58,208,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMVT

    News

    Cantor Fitzgerald reiterates Immunovant stock Overweight rating

    Cantor Fitzgerald maintained its Overweight rating on Immunovant (NASDAQ:IMVT) after reviewing the company's first-quarter earnings report, which led to an update in their financial model primarily for operating expenses. The stock has seen a significant 191% return over the past year, trading near its 52-week high, although InvestingPro data suggests it may be overvalued relative to its Fair Value estimate. Immunovant is a clinical-stage biopharmaceutical company focused on treatments for autoimmune diseases, and the Overweight rating implies an expectation of outperformance over the next 12-18 months.

    Investing.com India•8/25/26•
    Bullish

    UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating

    UBS has increased its price target for Immunovant (IMVT) to $40 from $24, while reiterating a Neutral rating on the stock. This adjustment reflects an updated valuation for the company.

    Moomoo•8/24/26•
    Somewhat-Bullish

    Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Strategic Portfolio Adjustment

    Deep Track Capital, LP significantly reduced its stake in Immunovant Inc (IMVT) by 18.96% on June 30, 2026, selling 2,185,820 shares at $38.53 each. This strategic move, which had a -1.38% impact on the firm's portfolio, still leaves Deep Track Capital with a substantial holding of 9,341,151 shares, representing 5.96% of its total portfolio. The adjustment reflects the healthcare-focused investment firm's active risk management, potentially locking in gains following Immunovant's stock appreciation, while maintaining long-term conviction in the clinical-stage immunology company.

    GuruFocus•8/21/26•
    Somewhat-Bearish

    Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

    Kuehn Law, PLLC is investigating whether officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders due to potential self-dealing. The firm is encouraging long-term IMVT stockholders to contact them, as they may be entitled to damages and corporate governance reforms. The consultation is free, and the firm covers all case costs.

    Morningstar•8/20/26•
    Bearish

    Investigation launched into Immunovant officers for possible self-dealing harming shareholders

    Kuehn Law, PLLC has initiated an investigation into potential breaches of fiduciary duties by officers and directors of Immunovant, Inc., citing possible self-dealing. This probe could lead to financial damages for shareholders and changes in the company's corporate governance. Long-term shareholders are encouraged to seek legal counsel promptly due to potential time limitations for action.

    Pluang•8/20/26•
    Bearish

    Frequently Asked Questions About IMVT

    Does IMVT pay dividends?
    Immunovant Inc (IMVT) does not currently pay a regular dividend.
    What is IMVT's market cap?
    Immunovant Inc (IMVT) has a market capitalization of $8.43B with a current stock price of $40.82.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In